Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1979 Jun;39(6):648–658. doi: 10.1038/bjc.1979.116

Effects of carrageenan, PVP and tumour-bearer serum on immunity induced by excision or mitomycin C-treated tumour cells in mice

R Kearney, R L Wu, F Orr
PMCID: PMC2009980  PMID: 444404

Abstract

Carrageenan (Cg) was tested for its effects on the growth of, and immunity to, 2 methylcholanthrene-induced syngeneic murine fibrosarcomas (H1 and H2). The tumours were found not to share major tumour-specific transplantation antigens. H2 appeared more immunogenic than H1. In contrast to H1, immunity induced by H2 was not affected by Cg, nor was its growth in Cg-treated normal mice augmented.

Postoperative i.p. injections of Cg abolished the weak anti-H1 immunity produced by H1 tumour excision. Furthermore, the subsequent growth of the H1 tumour challenge in the Cg-treated immune mice was significantly greater than the augmented growth in Cg-treated normal mice. The Prior administration of the macrophage-stabilizing agent polyvinylpyrrolidone (PVP) to immune mice significantly reduced the augmenting effect of Cg. The growth-promoting effect of Cg on a secondary H1 tumour challenge in mice immunized by tumour excision was abolished by 106 MCT-H1 cells injected s.c. before Cg. In contrast to the immunity induced by tumour excision, Cg did not abolish the immunity induced by the injection of MCT-H1 cells.

Passive administration of H1 tumour-bearer serum (TBS) did not enhance the growth of H1 cells in normal mice, nor did TBS abrogate the specific cell-mediated immunity (CMI) induced in vivo by MCT-H1 cells. However, TBS administered to Cg-treated, MCT-H1-immune mice abolished tumour immunity.

We propose that TBS does not inhibit CMI in vivo provided that macrophages remain functional, but may do so when macrophages are rendered defective by antimacrophage agents or by products of neoplastic cells. Increasing the levels of specific effector cells can over-ride the inhibiting effects of TBS, even when defective macrophages are present.

Full text

PDF
648

Images in this article

654Fig. 6
on p.654

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander P., Evans R., Grant C. K. The interplay of lymphoid cells and macrophages in tumour immunity. Ann Inst Pasteur (Paris) 1972 Apr;122(4):645–658. [PubMed] [Google Scholar]
  2. Anderson W., Duncan J. G. The anticoagulant activity of carrageenan. J Pharm Pharmacol. 1965 Oct;17(10):647–654. doi: 10.1111/j.2042-7158.1965.tb07577.x. [DOI] [PubMed] [Google Scholar]
  3. Basten A., Miller J. F., Sprent J., Cheers C. Cell-to-cell interaction in the immune response. X. T-cell-dependent suppression in tolerant mice. J Exp Med. 1974 Jul 1;140(1):199–217. doi: 10.1084/jem.140.1.199. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Belehradek J., Jr, Barski G., Thonier M. Evolution of cell-mediated antitumor immunity in mice bearing a syngeneic chemically induced tumor. Influence of tumor growth, surgical removal and treatment with irradiated tumor cells. Int J Cancer. 1972 May 15;9(3):461–469. doi: 10.1002/ijc.2910090302. [DOI] [PubMed] [Google Scholar]
  5. Benjamini E., Fong S., Erickson C., Leung C. Y., Rennick D., Scibienski R. J. Immunity to lymphoid tumors in syngeneic mice by immunization with mitomycin C-treated cells. J Immunol. 1977 Feb;118(2):685–693. [PubMed] [Google Scholar]
  6. Catanzaro P. J., Schwartz H. J., Graham R. C., Jr Spectrum and possible mechanism of carrageenan cytotoxicity. Am J Pathol. 1971 Aug;64(2):387–404. [PMC free article] [PubMed] [Google Scholar]
  7. DAVIES G. E. INHIBITION OF COMPLEMENT BY CARRAGEENIN: MODE OF ACTION, EFFECT ON ALLERGIC REACTIONS AND ON COMPLEMENT OF VARIOUS SPECIES. Immunology. 1965 Mar;8:291–299. [PMC free article] [PubMed] [Google Scholar]
  8. Di Rosa M. Biological properties of carrageenan. J Pharm Pharmacol. 1972 Feb;24(2):89–102. doi: 10.1111/j.2042-7158.1972.tb08940.x. [DOI] [PubMed] [Google Scholar]
  9. Evans R., Alexander P. Rendering macrophages specifically cytotoxic by a factor released from immune lymphoid cells. Transplantation. 1971 Sep;12(3):227–229. doi: 10.1097/00007890-197109000-00015. [DOI] [PubMed] [Google Scholar]
  10. Evans R. Macrophages and the tumour bearing host. Br J Cancer Suppl. 1973 Aug;1:19–25. [PMC free article] [PubMed] [Google Scholar]
  11. Gillespie G. Y., Hansen C. B., Hoskins R. G., Russell S. W. Inflammatory cells in solid murine neoplasms. IV. Cytolytic T lymphocytes isolated from regressing or progressing Moloney sarcomas. J Immunol. 1977 Aug;119(2):564–570. [PubMed] [Google Scholar]
  12. Haskill J. S., Proctor J. W., Yamamura Y. Host responses with solid tumors. I. Monocytic effector cells within rat sarcomas. J Natl Cancer Inst. 1975 Feb;54(2):387–393. [PubMed] [Google Scholar]
  13. Hochschild R. Effects of various additives on in vitro survival time of mouse macrophages. J Gerontol. 1973 Oct;28(4):447–449. doi: 10.1093/geronj/28.4.447. [DOI] [PubMed] [Google Scholar]
  14. Kearney R., Basten A., Nelson D. S. Cellular basis for the immune response to methylcholanthrene-induced tumors in mice. Heterogeneity of effector cells. Int J Cancer. 1975 Mar 15;15(3):438–450. doi: 10.1002/ijc.2910150310. [DOI] [PubMed] [Google Scholar]
  15. Kearney R., Nelson D. S. Concomitant immunity to syngeneic methylcholanthrene-induced tumours in mice. Occurrence and specificity of concomitant immunity. Aust J Exp Biol Med Sci. 1973 Dec;51(6):723–735. doi: 10.1038/icb.1973.70. [DOI] [PubMed] [Google Scholar]
  16. Keller R. Promotion of tumor growth in vivo by antimacrophage agents. J Natl Cancer Inst. 1976 Dec;57(6):1355–1361. doi: 10.1093/jnci/57.6.1355. [DOI] [PubMed] [Google Scholar]
  17. Kripke M. L., Norbury K. C., Gruys E., Hibbs J. B., Jr Effects of trypan blue treatment on the immune responses of mice. Infect Immun. 1977 Jul;17(1):121–129. doi: 10.1128/iai.17.1.121-129.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Le François D., Youn J. K., Belehradek J., Jr, Barski G. Evolution of cell-mediated immunity in mice bearing tumors produced by a mammary carcinoma cell line. Influence of tumor growth, surgical removal, and treatment with irradiated tumor cells. J Natl Cancer Inst. 1971 May;46(5):981–987. [PubMed] [Google Scholar]
  19. Nelson D. S., Hopper K. E., Blanden R. V., Gardner I. D., Kearney R. Failure of immunogenic tumors to elicit cytolytic T cells in syngeneic hosts. Cancer Lett. 1978 Aug;5(2):61–67. doi: 10.1016/s0304-3835(78)80046-9. [DOI] [PubMed] [Google Scholar]
  20. Nelson M., Nelson D. S. Macrophages and resistance to tumours: influence of agents affecting macrophages and delayed-type hypersensitivity on resistance to tumours inducing concomitant immunity. Aust J Exp Biol Med Sci. 1978 Apr;56(2):211–223. [PubMed] [Google Scholar]
  21. Pilch Y. H., Riggins R. S. Antibodies to spontaneous and methylcholanthrene-induced tumors in inbred mice. Cancer Res. 1966 May;26(5):871–875. [PubMed] [Google Scholar]
  22. Plata F., Sordat B. Murine sarcoma virus (MSV)-induced tumors in mice. I. Distribution of MSV-immune cytolytic T lymphocytes in vivo. Int J Cancer. 1977 Feb 15;19(2):205–211. doi: 10.1002/ijc.2910190210. [DOI] [PubMed] [Google Scholar]
  23. Rios A., Simmons R. L. Poly-2-vinylpyridine N-oxide reverses the immunosuppressive effects of silica and carrageenan. Transplantation. 1972 Mar;13(3):343–345. doi: 10.1097/00007890-197203000-00026. [DOI] [PubMed] [Google Scholar]
  24. Russell S. W., Doe W. F., Hoskins R. G., Cochrane C. G. Inflammatory cells in solid murine neoplasms. I. Tumor disaggregation and identification of constituent inflammatory cells. Int J Cancer. 1976 Sep 15;18(3):322–330. doi: 10.1002/ijc.2910180309. [DOI] [PubMed] [Google Scholar]
  25. Simes R. J., Kearney R., Nelson D. S. Role of a non-committed accessory cell in the in vivo suppression of a syngeneic tumour by immune lymphocytes. Immunology. 1975 Aug;29(2):343–351. [PMC free article] [PubMed] [Google Scholar]
  26. Thomson A. W., Fowler E. F. Potentiation of tumour growth by carrageenan. Transplantation. 1977 Nov;24(5):397–400. [PubMed] [Google Scholar]
  27. Van Loveren H., Den Otter W. Macrophages in solid tumors. I. Immunologically specific effector cells. J Natl Cancer Inst. 1974 Oct;53(4):1057–1060. doi: 10.1093/jnci/53.4.1057. [DOI] [PubMed] [Google Scholar]
  28. Zarling J. M., Tevethia S. S. Transplantation immunity to simian virus 40-transformed cells in tumor-bearing mice. II. Evidence for macrophage participation at the effector level of tumor cell rejection. J Natl Cancer Inst. 1973 Jan;50(1):149–157. doi: 10.1093/jnci/50.1.149. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES